2018
Afiuni-Zadeh S, Boylan KLM, Jagtap PD, Griffin TJ, Rudney JD, Peterson ML, Skubitz APN.
Hashemi MM, Rovig J, Holden BS, Taylor MF, Weber S, Wilson J, Hilton B, Zaugg AL, Ellis SW, Yost CD, Finnegan PM, Kistler CK, Berkow EL, Deng S, Lockhart SR, Peterson M, Savage PB.
Alpha-Toxin Contributes to Biofilm Formation among Staphylococcus aureus Wound Isolates
Hashemi MM, Rovig J, Holden BS, Taylor MF, Weber S, Wilson J, Hilton B, Zaugg AL, Ellis SW, Yost CD, Finnegan PM, Kistler CK, Berkow EL, Deng S, Lockhart SR, Peterson M, Savage PB.
2017
AN Gillman, LM Breshears, CK Kistler, PM Finnegan, VJ Torres, PM Schlievert, ML Peterson.
2016
Protocol for Examining Human Vaginal Epithelial Cell Signaling in Response to Staphylococcal Superantigens. Breshears LM, Peterson ML. Methods in molecular biology (Clifton, N.J.). 2016; 1396:149-58.
Local Epidermal Growth Factor Receptor Signaling Mediates the Systemic Pathogenic Effects of Staphylococcus aureus Toxic Shock Syndrome.
LM Breshears, AN Gillman, CS Stach, PM Schlievert, ML Peterson.
The Acinetobacter baumannii Two-Component System AdeRS Regulates Genes Required for Multidrug Efflux, Biofilm Formation, and Virulence in a Strain-Specific Manner
Grace E. Richmond, Laura P. Evans, Michele J. Anderson, Matthew E. Wand, Laura C. Bonney, Alasdair Ivens, Kim Lee Chua, Mark A. Webber, J. Mark Sutton, Marnie L. Peterson, and Laura J. V. Piddock.
2015
Efficacy of skin and nasal povidone-iodine preparation against mupirocin-resistant methicillin-resistant Staphylococcus aureus and S. aureus within the anterior nares. Anderson MJ, David ML, Scholz M, Bull SJ, Morse D, Hulse-Stevens M, Peterson ML. Antimicrob Agents Chemother. 2015 May;59(5):2765-73. doi: 10.1128/AAC.04624-14. Epub 2015 Mar 2.
Glycerol Monolaurate Microbicide Protection against Repeat High-Dose SIV Vaginal Challenge. Haase AT, Rakasz E, Schultz-Darken N, Nephew K, Weisgrau KL, Reilly CS, Li Q, Southern PJ, Rothenberger M, Peterson ML, Schlievert PM. PloS one. 2015; 10(6):e0129465.
Lactobacillus crispatus inhibits growth of Gardnerella vaginalis and Neisseria gonorrhoeae on a porcine vaginal mucosa model. Breshears LM, Edwards VL, Ravel J, Peterson ML. BMC microbiology. 2015; 15:276.
2014
Testing for resistance genes in bacteria is one way to fight the antibiotic crisis.
Peterson ML. The Conversation: Longitude Prize worth £10m to go to researchers who target antibiotic-resistant bugs. (2014 June 26)
Cell permeable vanX inhibitors as vancomycin re-sensitizing agents. Muthyala R, Rastogi N, Shin WS, Peterson ML, Sham YY. Bioorg Med Chem Lett. 2014 Jun 1;24(11):2535-8. doi: 10.1016/j.bmcl.2014.03.097. Epub 2014 Apr 8.
Vaccination against Staphylococcus aureus pneumonia. Spaulding AR, Salgado-Pabón W, Merriman JA, Stach CS, Ji Y, Gillman AN, Peterson ML, Schlievert PM. The Journal of infectious diseases. 2014; 209(12):1955-62.
2013
A mucosal model to study microbial biofilm development and anti-biofilm therapeutics. Anderson MJ, Parks PJ, Peterson ML. J Microbiol Methods. 2013 Feb 15;92(2):201-8. doi: 10.1016/j.mimet.2012.12.003. Epub 2012 Dec 14.
Ex vivo porcine vaginal mucosal model of infection for determining effectiveness and toxicity of antiseptics. Anderson MJ, Scholz MT, Parks PJ, Peterson ML. J Appl Microbiol. 2013 Sep;115(3):679-88. doi: 10.1111/jam.12277. Epub 2013 Jul 8.
Superantigens are critical for Staphylococcus aureus Infective endocarditis, sepsis, and acute kidney injury. Salgado-Pabón W, Breshears L, Spaulding AR, Merriman JA, Stach CS, Horswill AR, Peterson ML, Schlievert PM. mBio. 2013; 4(4).
2012
Alpha-toxin promotes Staphylococcus aureus mucosal biofilm formation.
Anderson MJ, Lin YC, Gillman AN, Parks PJ, Schlievert PM, Peterson ML.
Front Cell Infect Microbiol. 2012;2:64. doi: 10.3389/fcimb.2012.00064. Epub 2012 May 9. PMID: 22919655 [PubMed – in process]
A disintegrin and metalloproteinase 17 (ADAM17) and epidermal growth factor receptor (EGFR) signaling drive the epithelial response to Staphylococcus aureus toxic shock syndrome toxin-1 (TSST-1). Breshears LM, Schlievert PM, Peterson ML.
J Biol Chem. 2012 Sep 21;287(39):32578-87. Epub 2012 Jul 25. PMID: 22833676 [PubMed – indexed for MEDLINE
Immunity to Staphylococcus aureus secreted proteins protects rabbits from serious illnesses. Spaulding AR, Lin YC, Merriman JA, Brosnahan AJ, Peterson ML, Schlievert PM. Vaccine. 2012 Jul 20;30(34):5099-109. doi: 10.1016/j.vaccine.2012.05.067. Epub 2012 Jun 9.
Epithelial proinflammatory response and curcumin-mediated protection from staphylococcal toxic shock syndrome toxin-1. Schaefers MM, Breshears LM, Anderson MJ, Lin YC, Grill AE, Panyam J, Southern PJ, Schlievert PM, Peterson ML. PLoS One. 2012;7(3):e32813. doi: 10.1371/journal.pone.0032813. Epub 2012 Mar 14.
Glycerol monolaurate antibacterial activity in broth and biofilm cultures. Schlievert PM, Peterson ML. PLoS One. 2012;7(7):e40350. doi: 10.1371/journal.pone.0040350. Epub 2012 Jul 11.
Comparison of Staphylococcus aureus strains for ability to cause infective endocarditis and lethal sepsis in rabbits. Spaulding AR, Satterwhite EA, Lin YC, Chuang-Smith ON, Frank KL, Merriman JA, Schaefers MM, Yarwood JM, Peterson ML, Schlievert PM. Frontiers in cellular and infection microbiology. 2012; 2:18.
Immunity to Staphylococcus aureus secreted proteins protects rabbits from serious illnesses. Spaulding AR, Lin YC, Merriman JA, Brosnahan AJ, Peterson ML, Schlievert PM. Vaccine. 2012; 30(34):5099-109. NIHMSID: NIHMS387692
A disintegrin and metalloproteinase 17 (ADAM17) and epidermal growth factor receptor (EGFR) signaling drive the epithelial response to Staphylococcus aureus toxic shock syndrome toxin-1 (TSST-1). Breshears LM, Schlievert PM, Peterson ML. The Journal of biological chemistry. 2012; 287(39):32578-87.
2011
Proinflammatory exoprotein characterization of toxic shock syndrome Staphylococcus aureus. Lin YC, Anderson MJ, Kohler PL, Strandberg KL, Olson ME, Horswill AR, Schlievert PM, Peterson ML. Biochemistry. 2011 Aug 23;50(33):7157-67. doi: 10.1021/bi200435n. Epub 2011 Jul 21.
2010
Efficacy of concurrent application of chlorhexidine gluconate and povidone iodine against six nosocomial pathogens. Anderson MJ, Horn ME, Lin YC, Parks PJ, Peterson ML. Am J Infect Control. 2010 Dec;38(10):826-31. doi: 10.1016/j.ajic.2010.06.022. Epub 2010 Oct 30
Staphylococcus aureus exotoxins are present in vivo in tampons. Schlievert PM, Nemeth KA, Davis CC, Peterson ML, Jones BE. Clin Vaccine Immunol. 2010 May;17(5):722-7. doi: 10.1128/CVI.00483-09. Epub 2010 Mar 24
New insights into the prevention of staphylococcal infections and toxic shock syndrome. Lin YC, Peterson ML. Expert Rev Clin Pharmacol. 2010 Nov 1;3(6):753-767.
Glycerol monolaurate inhibits Candida and Gardnerella vaginalis in vitro and in vivo but not Lactobacillus. Strandberg KL, Peterson ML, Lin YC, Pack MC, Chase DJ, Schlievert PM. Antimicrob Agents Chemother. 2010 Feb;54(2):597-601. doi: 10.1128/AAC.01151-09. Epub 2009 Dec 14.
Enterococcus faecalis endocarditis severity in rabbits is reduced by IgG Fabs interfering with aggregation substance. Schlievert PM, Chuang-Smith ON, Peterson ML, Cook LC, Dunny GM. PloS one. 2010; 5(10).
2009
Glycerol monolaurate prevents mucosal SIV transmission. Li Q, Estes JD, Schlievert PM, Duan L, Brosnahan AJ, Southern PJ, Reilly CS, Peterson ML, Schultz-Darken N, Brunner KG, Nephew KR, Pambuccian S, Lifson JD, Carlis JV, Haase AT. Nature. 2009 Apr 23;458(7241):1034-8. doi: 10.1038/nature07831. Epub 2009 Mar 4.
Glycerol monolaurate and dodecylglycerol effects on Staphylococcus aureus and toxic shock syndrome toxin-1 in vitro and in vivo. Lin YC, Schlievert PM, Anderson MJ, Fair CL, Schaefers MM, Muthyala R, Peterson ML. PLoS One. 2009 Oct 19;4(10):e7499. doi: 10.1371/journal.pone.0007499.
Cytolysins augment superantigen penetration of stratified mucosa. Brosnahan AJ, Mantz MJ, Squier CA, Peterson ML, Schlievert PM. Journal of immunology (Baltimore, Md. : 1950). 2009; 182(4):2364-73. NIHMSID: NIHMS164861
Reduction in Staphylococcus aureus growth and exotoxin production and in vaginal interleukin 8 levels due to glycerol monolaurate in tampons. Strandberg KL, Peterson ML, Schaefers MM, Case LC, Pack MC, Chase DJ, Schlievert PM. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2009; 49(11):1711-7.
Staphylococcal toxic shock syndrome erythroderma is associated with superantigenicity and hypersensitivity. John CC, Niermann M, Sharon B, Peterson ML, Kranz DM, Schlievert PM. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2009; 49(12):1893-6. NIHMSID: NIHMS146828
2008
Novel toxic shock syndrome toxin-1 amino acids required for biological activity. Brosnahan AJ, Schaefers MM, Amundson WH, Mantz MJ, Squier CA, Peterson ML, Schlievert PM. Biochemistry. 2008
Glycerol monolaurate does not alter rhesus macaque (Macaca mulatta) vaginal lactobacilli and is safe for chronic use. Schlievert PM, Strandberg KL, Brosnahan AJ, Peterson ML, Pambuccian SE, Nephew KR, Brunner KG, Schultz-Darken NJ, Haase AT. Antimicrob Agents Chemother. 2008 Dec;52(12):4448-54. doi: 10.1128/AAC.00989-08. Epub 2008 Oct 6.
2007
Vaginal Staphylococcus aureus superantigen profile shift from 1980 and 1981 to 2003, 2004, and 2005. Schlievert PM, Case LC, Strandberg KL, Tripp TJ, Lin YC, Peterson ML J Clin Microbiol. 2007 Aug;45(8):2704-7. Epub 2007 May 30.
Alpha and beta chains of hemoglobin inhibit production of Staphylococcus aureus exotoxins. Schlievert PM, Case LC, Nemeth KA, Davis CC, Sun Y, Qin W, Wang F, Brosnahan AJ, Mleziva JA,Peterson ML, Jones BE. Biochemistry. 2007 Dec 18;46(50):14349-58. Epub 2007 Nov 20.
Neutralization of staphylococcal enterotoxin B by soluble, high-affinity receptor antagonists. Buonpane RA, Churchill HR, Moza B, Sundberg EJ, Peterson ML, Schlievert PM, Kranz DM. Nat Med. 2007 Jun;13(6):725-9. Epub 2007 May 21.
2006
Glycerol monolaurate inhibits the effects of Gram-positive select agents on eukaryotic cells. Peterson ML, Schlievert PM. Biochemistry. 2006 Feb 21;45(7):2387-97.
2005
The innate immune system is activated by stimulation of vaginal epithelial cells with Staphylococcus aureus and toxic shock syndrome toxin 1. Peterson ML, Ault K, Kremer MJ, Klingelhutz AJ, Davis CC, Squier CA, Schlievert PM.
Purpura fulminans due to Staphylococcus aureus. Kravitz GR, Dries DJ, Peterson ML, Schlievert PM. Clin Infect Dis. 2005 Apr 1;40(7):941-7. Epub 2005 Mar 2.
2004
Role of topoisomerase mutations and efflux in fluoroquinolone resistance of Bacteroides fragilis clinical isolates and laboratory mutants. Ricci V, Peterson ML, Rotschafer JC, Wexler H, Piddock LJ. Antimicrobial agents and chemotherapy. 2004; 48(4):1344-6.
Reemergence of staphylococcal toxic shock syndrome in Minneapolis-St. Paul, Minnesota, during the 2000-2003 surveillance period. Schlievert PM, Tripp TJ, Peterson ML. Journal of clinical microbiology. 2004; 42(6):2875-6.
2003
Plasmid-mediated complementation of gyrA and gyrB in fluoroquinolone-resistant Bacteroides fragilis. Peterson ML, Rotschafer JC, Piddock LJ. The Journal of antimicrobial chemotherapy. 2003; 52(3):481-4.
2002
Pharmacodynamics of trovafloxacin and levofloxacin against Bacteroides fragilis in an in vitro pharmacodynamic model. Peterson ML, Hovde LB, Wright DH, Brown GH, Hoang AD, Rotschafer JC. Antimicrobial agents and chemotherapy. 2002; 46(1):203-10.
2001
Fluoroquinolone resistance in anaerobic bacteria following exposure to levofloxacin, trovafloxacin, and sparfloxacin in an in vitro pharmacodynamic model. Ross GH, Wright DH, Hovde LB, Peterson ML, Rotschafer JC. Antimicrobial agents and chemotherapy. 2001; 45(7):2136-40.
2000
Application of fluoroquinolone pharmacodynamics. Wright DH, Brown GH, Peterson ML, Rotschafer JC. The Journal of antimicrobial chemotherapy. 2000; 46(5):669-83.
1999
Fluoroquinolone resistance in Bacteroides fragilis following sparfloxacin exposure. Peterson ML, Hovde LB, Wright DH, Hoang AD, Raddatz JK, Boysen PJ, Rotschafer JC. Antimicrobial agents and chemotherapy. 1999; 43(9):2251-5.
1996
Pharmacy involvement in and use of critical pathways in Minnesota hospitals. Seay R, O’Connell MB, Peterson M. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 1996; 53(16):1950-2.